%0 Journal Article
%T Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker?<br>
%A Guo Yong-Fang
%A An Yi
%A <br>
%J 老年心脏病学杂志(英文版)
%D 2011
%I Science Press
%X 1 IntroductionBeta-adrenoceptor blocking agents (beta-blockers) are now well established as cornerstone therapy in patients with systolic chronic heart failure (CHF).1] Clinical data have overwhelmingly proven the beneficial effects of beta-blocker therapy in terms of improving patient prognosis,decreasing requirements for hospitalization,and postponing disease progression.2-4] However,it remains unclear what the optimal efficacious and safe dose for an individual patient with CHF is,and whether this can simply be inferred from the target dose for each beta-blocking agent as used in the major clinical trials.Beta-blockers are a heterogeneous class of drugs,and due to the polymorphisms of beta-adrenoceptor gene expression,there is marked individual variation in responsiveness to specific agents.5] If pharmacodynamic markers of responsiveness to beta-blockade (such as heart rate (HR) reduction) are more important than the achievement of a target dose,could they become another potential therapeutic target in beta-blocker therapy? We provide a discussion of the question in this article.
%K heart rate
%K beta-blockers
%K chronic heart failure<br>
%U http://www.alljournals.cn/get_abstract_url.aspx?pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=AD36F34DDC3BA7B0&jid=4DC702B3A2386A4814E2FF9CFB799B27&aid=F6A18BF18450BB18669E176C7B2EA0B4&yid=9377ED8094509821&vid=5D311CA918CA9A03&iid=E158A972A605785F&sid=89AC6B0ADBEA2741&eid=30897FA31CA3354D&journal_id=1671-5411&journal_name=Journalofgeriatriccardiology:JGC&referenced_num=0&reference_num=21